Resilience cuts 120 employees at a former bluebird gene therapy site

This latest round of workforce cuts affects workers from its Research Triangle Park factory in Durham, NC, according to a WARN notice on Monday. The layoffs will take effect on Dec. 15 this year, according to the notice.

“We have made the decision to right-size our RTP facility based on demand in the gene therapy sector, which requires reducing headcount in parts of our network while simultaneously growing it in other parts,” a Resilience spokesperson told Endpoints News.

Resilience bought the Durham site for $110 million from bluebird bio in July 2021. It has clinical and commercial gene therapy manufacturing capabilities. The CDMO will continue commercial development and manufacturing, the Resilience spokesperson said.

Resilience has seven other facilities in North America. The CDMO previously laid off more than 105 staffers from its site in Alachua, FL, on the same day as new CEO William Marth took charge, replacing his predecessor Rahul Singhvi. In February 2023, Resilience also cut around 213 employees from its manufacturing facility in Allston, MA.

Meanwhile, Resilience also said Wednesday it has extended an autoimmune partnership with Parvus Therapeutics to manufacture its Phase 1/2 inflammatory bowel disease asset PVT401.

Further, Resilience announced a $225 million investment into its Cincinnati, OH, biologics and vaccine facility in February 2024. Resilience has been raking in cash from its GLP-1 work, driving predictions of 30% year-on-year increases in overall revenue growth over the next few years.

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Related Services